Tesamorelin vs CJC-1295
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
Research literature describes tesamorelin as a growth hormone–releasing factor (growth hormone-releasing hormone) analogue that is FDA-approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy, with clinical studies reporting effects on visceral fat and related body-composition outcomes in that indication. Orthopaedic/sports-medicine reviews note a lack of supporting orthopaedic evidence for tesamorelin and identify broader gaps in clinical evidence for “injectable peptide therapy” in musculoskeletal contexts.
CJC-1295 is described as a long-acting growth-hormone-releasing hormone (GHRH) analog. Clinical research in healthy adults reported sustained, dose-dependent increases in circulating growth hormone (GH) and insulin-like growth factor I (IGF-I) after subcutaneous administration, with effects persisting for days and no serious adverse reactions reported in the studied cohorts.
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Family | GHRH analogs | GHRH analogs |
| Research goals | Metabolic & weight, GH axis support | GH axis support |
| Amino acids | — | — |
| Molecular formula | C221H366N72O67S | C165H269N47O46 |
| Molecular weight | 5136 g/mol | 3647.2 g/mol |
| CAS number | 218949-48-5 | 446262-90-4 |
| Approx. half-life | — | — |
| Regulatory status | Unknown | Unknown |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 9 | 8 |
| Vendors independently tested | 47 | 48 |
| Best test score (Finnrick) | 8.3 | 9.1 |